Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

Nature Genetics

Volumn 22, Issue 2, 1999, Pages 168-170

  Drazen, Jeffrey M ^a   Yandava, Chandri N ^a   Dubé, Louise ^b   Szczerback, Natalie ^b   Hippensteel, Richard ^b   Pillari, Antonino ^a   Israel, Elliot ^a   Schork, Nicholas ^c   Silverman, Eric S ^a   Katz, David A ^b   Drajesk, Jeffrey ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Genset Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; ENZYME INHIBITOR; LEUKOTRIENE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; REPORTER GENE; TRANSCRIPTION REGULATION;

EID: 0033059209     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/9680     Document Type: Article

References (25)

1. Barnes, P.J. Drug therapy: inhaled glucocorticoids for asthma. N. Engl. J. Med. 332, 868-875 (1995).
2. Lemanske, R.F. & Busse, W.W. Asthma. JAMA 278, 1855-1873 (1997).
3. Busse, W.W. Leukotrienes and inflammation. Am. J. Respir. Crit. Care Med. 157, 5210-5213 (1998).
4. Drazen, J.M., Israel, E. & Obyrne, P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 340, 197-206 (1999).
5. Obyrne, P.M., Israel, E. & Drazen, J.M. Antileukotrienes in the treatment of asthma. Ann. Intern. Med. 127, 472-480 (1997).
6. In, K.H. et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 99, 1130-1137 (1997).
7. Silverman, E.S. et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am. J. Respir. Cell Mol. Biol. 19, 316-323 (1998).
8. Stankova, J., Rolapleszczynski, M. & Dubois, C.M. Granulocyte-macrophage colony-stimulating factor increases 5-lipoxygenase gene transcription and protein expression in human neutrophils. Blood 85, 3719-3726 (1995).
9. Mcgill, K.A. & Busse, W.W. Zileuton. Lancet 348, 519-524 (1996).
10. Schwartz, H.J., Petty, T., Dube, L.M., Swanson, L.J. & Lancaster, J.F. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. Arch. Intern. Med. 158, 141-148 (1998).
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. Rev. Respir. Dis. 136, 225-244 (1987).
12. Wong, S.L. et al. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. Clin. Pharmacol. Ther. 63, 324-331 (1998).
13. Wong, S.L. et al. Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. Eur. J. Clin. Pharmacol. 54, 715-719 (1998).
14. Barnes, P.J. Neuropeptides in human airways: function and clinical implications. Am. Rev. Respir. Dis. 136, S77-S83 (1987).
15. Smith, L.J. The role of platelet-activating factor in asthma. Am. Rev. Respir. Dis. 143, S100-S102 (1991).
16. Wenzel, S.E., Fowler, A.A. & Schwartz, L.B. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am. Rev. Respir. Dis. 137, 1002-1008 (1988).
17. Nadel, J.A. & Caughey, G.H. Roles of mast cell proteases in airways. Chest 95, 1328-1330 (1989).
18. Nebert, D.W. & Weber, W.W. Pharmacogenetics, in Principles of Drug Action: The Basis of Pharmacology (Churchill Livingston, New York, 1990).
19. Meyer, U.A. & Zanger, U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
20. Carson, P.E., Flangan, C.L., Ickes, C.E. & Alving, A.S. Enzymatic deficiency in primaquine sensitive erythrocytes. Science 124, 484-485 (1956).
21. Poort, S.R., Rosendaal, F.R., Reitsma, P.H. & Bertina, R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88, 3698-3703 (1996).
22. Arranz, M. et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281-282 (1995).
23. Kuivenhoven, J.A. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338, 86-93 (1998).
24. Hancox, R.J., Sears, M.R. & Taylor, D.R. Polymorphism of the β(2)-adrenoceptor and the response to long-term β(2)-agonist therapy in asthma. Eur. Respir. J. 11, 589-593 (1998).
25. American Thoracic Society. Standardization of spirometry - 1987 update. Am. Rev. Respir. Dis. 136, 1285-1298 (1987).